Get started

Biotech

MIRO Miromatrix Medical Price TargetMiromatrix Medical Inc. engages in the development of biological human organs to solve the chronic shortage of transplantable organs. 114,000 people in the U.S. are waiting for a life-saving organ transplant, and more than half will die due to a lack of available organs. Miromatrix Medical trial is expected to begin in the second half of 2022 and will assess the function of a bioengineered liver in humans via an external application. if it succeeds, the opportunity to buy the stock at these prices will be history. The Market Cap of MIRO is just 214.74Mil On 7/19/2021 Craig Hallum brokerage Initiated Coverage with a Buy rating and a $22.00 price target
MLong
by TopgOptions
$ESPR Short squeeze - 1 D Candle I think ESPR could start to get interested in this level . - After a long decline from the peak ($ 40) this year, on 27/1/2021, we are now witnessing a consolidation in the price level. - I do not look at fundamental information, only technical data . Indicators : * EMA21 is the purple line * EMA9 is the green line * Consolidation at Slow Stochastic * RSI begins to change direction - 26.23M short float (low float) - Setup: Falling Wedge - Short floating percentage 32.48% - Above the consolidation at 15$ squeeze can happen * It can be very aggressive .. think of all the Short's sellers who will have to cover positions after they see a price level break after consolidation ... * No financial advice just my personal opinion, make your own DD!
NASDAQ:ESPRLong
by SaTLla101
ABCL - 20-30% UPSIDE - LONGAll, ABCL is for massively oversold on weekly down so regardless how you feel about the stock (even though price target analysts are WAY higher) this is due for a rip. Not to mention this is a perfect situation for institutions to enter into ABCL at a pretty big discount from fair value etc. I am temporarily waiting next few days watch it extremely closely then entering unless it breaks through the bottom. Feel free to do your DD on ABCL they actually have really good positive pipelines just being held down.
NASDAQ:ABCLLong
by DigitalData
INO What You're Thinking...INO finally broke back above the 786 fib line. Before the last bout of selling, you'll see this level was an area of support for the former penny stock. Now, thanks to some added excitement from delta news (the variant not the airline), INO shares are popping. They also jumped back above the 786 fib. Now the question is, will it rest the 618 fib like it tried to a few weeks ago? "Inovio Pharmaceuticals Inc. (NASDAQ: INO) has steadily climbed for the better part of the last 3 months thanks to recent pipeline progress. In June, the company had expanded its partnership with Advaccine Biopharmaceuticals Suzhou to conduct a Phase 3 segment of a trial called INNOVATE. The goal is to evaluate the safety and efficacy of the company’s INO-4800 in COVID patients. The treatment was already shown to be well tolerated and immunogenic in tested age groups in a Phase 2 study. This month Inovio announced that it and Advaccine received a regulatory allowance for 2 heterologous prime-boost clinical trials in China using INO-4800. “VID-19. If approved, we believe INO-4800 will be well-positioned to serve the vaccine needs of the global community as both a primary and a booster vaccine due to its tolerability, balanced cross-reactive immune responses, and strong thermostability profile that does not require cold or ultra-cold-chain transport,” said Dr. J. Joseph Kim, President, and CEO of INOVIO." Quote Source & Read more on INO: Former Penny Stocks To Watch After Merck’s ( MRK ) Latest FDA Win
NASDAQ:INO
by PennyStocks101
1
LTRN Lower Float, Light Vol, Big News Now What?LTRN is a stranger to high volume. For the last 2 quarters, it hasn't traded more than 355k shares on a GOOD day. Many days even see less than 100k shares trade. The current OS on it is 11 M suggesting the float is, at the very most, 11 million as of the last reported OS. This morning the company announced FDA news and was granted Orphan Drug Designation for its LP-184 pancreatic cancer treatment. "This orphan designation is one of many upcoming milestones that we expect to achieve for our LP-184 program in pancreatic cancer. We recently reported that LP-184 demonstrated significant and rapid pancreatic tumor shrinkage, by over 90%, within in-vivo mouse models over 8 weeks.  In comparison, the tumors in the untreated mice grew by over eleven-fold in volume during the same 8-week period. We are excited to advance this groundbreaking research to help patients suffering from this devastating disease where the benefits of current treatment options are very limited." - Panna Sharma, President & CEO of Lantern Pharma. Taking a look at the chart and fib retracement using recent lows and the anchor, you can see how the 786 fib line has remained a consistent pivot on the chart. It was a previous support that LTRN bounced off of. Now, over more recent weeks it has become more of a resistance with the stock now treading water during premarket trading on Aug 11. Though LTRN has broken above the 50DMA for the first time in quite a while, it was rejected during premarket trading when it tested the 200DMA level around $16. Considering all of these major areas of focus, it will be interesting to see if enough momentum is in play for any meaningful move to persist or if LTRN will fall back once again. If there's one thing that has been in the spotlight this summer it has been cancer treatment stocks. Sanofi (SNY) Acquired Translate Bio (TBIO) Bristol Myers' (BMY) Opdivo Showed Significant Growth Merck's drug gained FDA approval CYTK broke out big sparking a biotech rally Fate Therapeutics Progressed with its trial You also had a bunch of momentum building off the back of biotech breakouts, in general this week. "a few former penny stocks on Robinhood raised eyebrows in the analyst community. In fact, these analysts have given targets between 23% and 368% higher than where these stocks currently trade." Quote Source & Read more: Hot Stocks To Watch On Robinhood With Analyst Targets Up To 368%
NASDAQ:LTRN
by PennyStocks101
FULC SendFULC news catalyst popped the stock into the previous gap and right back to testing this clear resistance level that was previous support. After plotting the fib retracement is looks like the 50 Fib line is an area that might need to set up as the higher support level if there's any hope of FULC sustaining higher levels. We'll have to see what happens next. "The company focuses on developing treatments for rare genetic diseases. including sickle cell disease. This week, the company announced key data that has helped drive momentum in the market and push shares of FULC stock higher. Fulcrum announced positive interim results from its ongoing single- and multiple ascending dose (SAD and MAD) Phase 1 trial with FTX-6058. This treatment targets patients with fetal hemoglobin (HbF) with the potential to treat hemoglobinopathies." Quote Source & Read More: Hot Stocks To Watch On Robinhood With Analyst Targets Up To 368%
NASDAQ:FULC
by PennyStocks101
RNA tech inaugurates the new Kondratiev biotech cycleModerna up $75 in a single day damn. $90 since I bought. Didn't buy at 346 when I posted about it but at the bottom of the pullback a bit below 400 on friday. More and more people are accepting the vaccine, and new shots are coming. And regular retail "dumb money", the one that creates bubble, has not paid attention to PFE & MRNA yet (somehow). These companies are more famous now than Coca-Cola or Bitcoin. The bubble has not even started yet. It is going to go GME. I've been saying that vaccine hesitancy was U shape with the morons on the left of the IQ curve not trusting it for silly reason, and the gifted on the right of the IQ bell not trusting it for valid reason & being misunderstood. I was dead right! I have also been saying that the propaganda was so stupid only morons would fall for it. Right again 🙃. Now scientifically proven! I'm not saying the vaccine is dangerous, just that the smartest people are the more skepticals, the ones that think for themselves and that don't just mindlessly follow what some celebrity says. There are plenty of reasons why they might be skepticals not just a "lizard psyops" (that's what the authorities tell to high school dropouts to get them to take the shot AND IT WORKS THEY FALL FOR THAT). And my guess is, and I am very certainly right again, that the PHDs hesistant are mostly the more healthy ones, with the old & fat having a better risk to reward taking it (even if we do not know for sure what the risks actually are, there is no stop loss here). So the most hesistant group is the PHDs, followed by (at the time) the "rednecks" (high school degree or less), and of course who is the least hesitant group? Bachelor & Master degrees. The dead average normies that think they are smart "I stoodid! I am edookataid!", the typical clueless idiot parrots that think they are smart for mindlessly repeating what they are told. Universities suck, no idea why the US doesn't follow the french system, China did. In the US it's even pay to win. Kids want the gov to spend more for their university so they can have fun. Science has proven I was right about the propaganda only working with morons: Vaccine hesitancy among the high school and less has gone, between January and May, from 35% to 20%. Meanwhile the PHDs hesitancy actually WENT UP! Lmao pesky nerds, it went from ~23% to 25% in May. www.medrxiv.org Fortunately for my investment the vast majority is convinced and will keep purchasing new vaccines and "booster shots" some hypocondriacs are even breaking the law to get several booster shots! Take as many as you want, as long as you (via the government) pay for them :) And fortunately for my investment, the ignorant high school dropouts are literally too stupid to read let alone understand the FUD written by these pesky hesitant PHDs. But when a celibrity wearing a clown nose burps and farts and tells them the vaccine will make them normal they listen, when the media says that people that don't get the vaccine are silly flat earthers they fall for it, when the media tells them they should vaccinate their 3 year old because of some magical reason they listen, when they say the vaccine is efficient BUT not efficient if other people don't take it BUT it's efficient after all because you won't make a "serious" case BUT other people still have to take it because it could mutate into a more serious version so you have to pressure other people to take it they listen and they can't figure out they're preparing public opinion for more vaccines in the near future. Pretty amazing that the constant hammering of propaganda, of every single trick in the books has ZERO effect on PHDS, no it even has a slight negative effect (maybe a few can be tricked by reverse psychology or something? Just annoy them enough till they hate you so much they do the opposite of what you claim you want), and the high school dropouts massively fall for childish first degree tricks that are so obvious they sometimes make me blush. It's actually useless to try and warn people of the risk. 1- High IQs will only change their minds if they find rational evidence, and if there is evidence about something they'll know about it. Plus they are arrogant c***s that think they're smarter than everyone else (because they are) and don't listen to anything anyone "probably inferior" says and are super stubborn. Easy to be confident when you have something to back it up with. 2- The mindless spineless sheep in the middle will mindlessly follow anything anyone screaming loud enough says, they wouldn't want to lose their average normie repetitive desk job. Their greatest fear is looking stupid because they know they aren't smart enough to understand all the intricacies and put their balls on the table (assert themselves) and say they know best than "the scientists" (wheareas the scientists can obviously), while they also know they are smarter than the low IQs they despise and fear being mistaken with. There is probably a lot of Dunning-Kruger effect going on in here too, with this group being smart enough to understand 2-3 things, but not smart enough to understand the whole picture and know that they don't know what they don't know. 3- The "in difficulty" group, the low IQs, well they have a natural distrust of science not sure why, I don't know because I didn't study it because I don't care about this group, I don't care because they have no money and therefore no money to lose to me and even if they sometimes have some even Bitcoin is too solid an investment for them they rather lose it in a regular (obvious) "2% a day" ponzi. I don't know. What I know is they fall for childish manipulation tactics, their whole life they've let someone else do the thinking for them, and they are the fuel to this rocket ship. And to be fair I don't despise them like I despise 2, but if they grow a third arm and drop dead big deal, not like we don't have enough deadweights on welfare. We got an ample supply of those, not to worry. What we are missing are more doctors, more inventors, more independant thinkers. We have to fight against the minsinformation! These scary FUD tactics are causing potential clients to hesitate 😠. It's not a "new experiment method" my own father was working on it (against cancer) when I was a baby. It's older than me. If people would just sponteanously combust we would know it. The hesitancy is more subtle than that, nothing regular folks should worry their little heads about 🙂 One of the reason why it's good to have a few individuals not take it is so we have a group to compare to. Rather than whine about conflicts of interests, come and profit from it, get your piece of the pie 🤑
NASDAQ:MRNA
by MrRenev
1
Can SAVA get back to $100 in the short term? $SAVA (Cassava Sciences) saw an insane rally in 2021 from $7 to $145 on the hopes that its groundbreaking Alzheimer's treatment will yield promising results never before seen in the history of the disease. Currently there are no Alzheimer's modifying therapies on the market and if the data surrounding Cassava's main drug, simufilam, is accurate then it could be the first of its kind. SAVA saw a sell-the-news event when it announced its promising results, suffering a 23% drop on July 29. Soon thereafter a Stat News article was released criticizing Cassava's results, citing a group of independent researchers. The stock dropped a total of 55% from highs. Is this a buying opportunity? Obviously we are largely delving in uncharted territory and financial analysts/traders won't be able to infer whether the science is reliable or not. However, traders know how market cycles largely work. There is often a second wave of optimism after negative news coverage (whether a short report or a hit piece), driven by those who are willing to speculate. SAVA is showing a bullish harami on the 1D and it has dropped to the Fibonacci golden pocket level, also at the 100 MA where it has routinely found support. This could be a buying opportunity for those who are in the market for a bit of risk. As long as #SAVA is above the 100 MA, I'm willing to hold it in the mid term and will ride the next wave of positive financial/medical news. Entry: $79 SL: soft SL with manual monitoring if it breaches the 100 MA TP: $88, $94, $100
NASDAQ:SAVALong
by TheTravel1ngTrader
Writing The SCPS?SCPS seeing another spike in trading volume late in the week (week of 8/1). After plotting out the fib retracement using "normal levels" and not ones from the crazy parabolic spike previously, you can see this 618 area has been a key support/resistance level. With the latest spark taking SCPS stock higher afterhours on 8/4, it so far managed to break back above the 618 area for the first time in weeks. No news, no filings, just social momo. But thanks to it being part of that "low float" crowd, it could be in the mix of possible "short squeeze stocks" that've grown in popularity. Looking at the deets...back in May there were a few fundamental developments to track: " the company announced that it received FDA approval for an Investigational New Drug Application for its lead drug candidate, CpG-STAT3siRNA. Now, a Phase 1 trial for B-cell non-Hodgkin lymphoma will begin at the City of Hope. This is a well-known research and treatment center for cancer, diabetes, and other diseases. More To Watch With SCPS Stock As a newer company, Scopus has only been public since December of 2020. The company initially raised just under $3 million from its IPO debut. While this wasn’t technically a penny stock initially, shares hovered around $5 earlier this month. That was, until the news on May 24th. Since the announcement, SCPS stock has surged past the $17 mark. Furthermore, even though it’s a newer company, analysts have also begun following the company closely. Benchmark Research started Scopus with a Speculative Buy rating as well as a price target of $20. Analyst Aydin Huseynov believes that the company’s STAT3 inhibitor gene therapy, CO-sTiRNA, has “a reasonable chance to show clinically relevant results” in recurrent and hard-to-treat aggressive Non-Hodgkin Lymphoma indications. Huseynov gave this outlook several months before today’s news and expected the IND submission during the second half of the year. " Quote Source & Read More: 3 Biotech Penny Stocks To Watch That Analysts Are Bullish On Today
S
by PennyStocks101
SAVA Stuck At 382It's interesting to see what happens after plotting out fib lines sometimes. SAVA , for instance...using the earlier lows and the recent high as anchors we can see that the 382 fib line has been a very clear area of both support and resistance almost to the exact mark. Sure 236 played this role before the Alzheimer's data but now SAVA has reset back to some familiar territory and, so far, is mimicking its trend before the big breakout, which is 382 fib resistance being an issue. Multiple times in the last few days, this area was tested and SAVA was rejected (including 8/3). BUT with the market seemingly building optimism, it could once again be an important area on the chart to be aware of. "The biotech industry is well known for volatility. When you’re talking about developing life-changing treatments, there’s a lot to account for. The phase trial process brings the potential for big progress but can also put the brakes on otherwise strong rallies in the market. We recently saw this with companies like Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSE: ANVS ), which were also former penny stocks. Both companies developing Alzheimer’s treatments revealed data that didn’t impress the market at all. In response, shares of both stocks plummeted." Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NASDAQ:SAVA
by PennyStocks101
BMY Flirting With Historic TerritoryWhen I say "historic" for BMY I'm not talking ATH but the stock's encroaching on an area that has been tested 3 times being rejected each time. This is the 236 fib area using 2016's high as the top anchor. It's been 5 years since BMY traded well above this area. But with the way attention is being placed on immunotherapy stocks, it could be something to keep in mind for BMY longs. " Both Bristol-Myers and Novartis recently gave updates on new FDA updates. Novartis’ NIS793 gained FDA Orphan Drug Designation, while Bristol-Myers’ recent earnings update revealed strong sales figures from its lead cancer drug, Opdivo...B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment. While things are still in the very early stages for B7 molecules, as a whole, early research is also finding new potential for targeted cancer treatments. For instance, Merck’s (NYSE: MRK ) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment ." Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NYSE:BMY
by PennyStocks101